CD274 and neoplasm: Combinations with anti-PD-1/PD-L1 therapy revealed a reduction in polymorphonuclear myeloid-derived suppressor cells while combining lenvatinib with anti-Gr-1 antibody showed an expanded myeloid-derived suppressor cell population along with enhanced anti-tumor effects compared with lenvatinib monotherapy.205